تحميل...

Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study

BACKGROUND: Our retrospective, international study aimed at evaluating the activity and safety of eribulin mesylate (EM) in pretreated metastatic breast cancer (MBC) in a routine clinical setting. METHODS: Patients treated with EM for a locally advanced or MBC between March 2011 and January 2014 wer...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	BMC Cancer
المؤلفون الرئيسيون:	Dell’Ova, Mélodie, De Maio, Eléonora, Guiu, Séverine, Roca, Lise, Dalenc, Florence, Durigova, Anna, Pinguet, Frédéric, Bekhtari, Khedidja, Jacot, William, Pouderoux, Stéphane
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	BioMed Central 2015
الموضوعات:	Research Article
الوصول للمادة أونلاين:	https://ncbi.nlm.nih.gov/pmc/articles/PMC4599752/ https://ncbi.nlm.nih.gov/pubmed/26449988 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1673-3
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study

مواد مشابهة